<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Plasmablastic <z:hpo ids='HP_0002665'>lymphoma</z:hpo> shares many morphologic features with plasmablastic plasma cell <z:mp ids='MP_0009440'>myeloma</z:mp> </plain></SENT>
<SENT sid="1" pm="."><plain>The activation of MYC oncogene in these <z:hpo ids='HP_0002665'>lymphomas</z:hpo> may be an important pathogenetic element associated with <z:e sem="disease" ids="C0149678" disease_type="Disease or Syndrome" abbrv="">Epstein-Barr virus infection</z:e> </plain></SENT>
<SENT sid="2" pm="."><plain>We describe herein an elderly man with a plasmablastic lymphoid <z:hpo ids='HP_0002664'>neoplasm</z:hpo> displaying unique morphologic, cytogenetic and clinical features </plain></SENT>
<SENT sid="3" pm="."><plain>This case might offer additional insights to the complex but fascinating topic of hybrid haemato-lymphoid <z:hpo ids='HP_0002664'>neoplasms</z:hpo> such as plasmablastic <z:hpo ids='HP_0002665'>lymphoma</z:hpo>-<z:mp ids='MP_0009440'>myeloma</z:mp> </plain></SENT>
<SENT sid="4" pm="."><plain>In addition, the patient responded to the treatment with <z:chebi fb="0" ids="52717">bortezomib</z:chebi> </plain></SENT>
<SENT sid="5" pm="."><plain>Newer antimyeloma agents such as <z:chebi fb="0" ids="52717">bortezomib</z:chebi> have shown promise in the treatment of these <z:hpo ids='HP_0002664'>neoplasms</z:hpo> and should further be explored for their therapy </plain></SENT>
<SENT sid="6" pm="."><plain>Copyright Â© 2012 John Wiley &amp; Sons, Ltd </plain></SENT>
</text></document>